The purpose of the study is to evaluate the effect of stable co-administered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy.
The completion of this project should permit the unveiling of a new neuronal mechanism supporting the lack of conscious experience during absences and pave the way for new clinical non-invasive strategies to interrupt ongoing seizure activity.
Becoming familiar with this new language can enable you and your doctor to better communicate about your treatment options, triggers to avoid, and what to expect in the future.
Researchers say pigs are promising preclinical research models for hippocampal-dependent human memory disorders.
Supernus Pharmaceuticals said it has agreed to acquire Biscayne Neurotherapeutics for up to $185 million, in a deal that adds a Phase I epilepsy candidate to the buyer’s pipeline of treatments for central nervous system disorders.
The epilepsy candidate, which Supernus will rename SPN-817, uses a novel synthetic form of huperzine A, an acetyl cholinesterase inhibitor that according to the company has a novel mechanism of action and has shown anticonvulsant activity in preclinical models for partial seizures and Dravet Syndrome.
Discover the latest about what's happening at CURE and in our community in the September 2018 CURE Update from Chief Scientific Officer, Dr. Laura Lubbers!
The timing of seizures may be linked to natural rhythms in around 80% of people with epilepsy, according to the largest study of individual patients' seizure cycles including more than 1,000 people, published in The Lancet Neurology journal.
Pediatric Epilepsy
We present one of the largest surgical series of pediatric polymicrogyria patients. Seizure outcomes were best with complete resection/disconnection of polymicrogyria. However, tailored resections based on electroclinical and neuroradiologic data can produce good outcomes and remain an appropriate strategy for patients with extensive polymicrogyria.
Adequate identification and management of electroencephalographic seizures with judicious use of anti-seizure medications may optimize outcomes.
